Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Sex-dependent behavioral deficits and neuropathology in a maternal immune activation model of autism.

Haida O, Al Sagheer T, Balbous A, Francheteau M, Matas E, Soria F, Fernagut PO, Jaber M.

Transl Psychiatry. 2019 Mar 28;9(1):124. doi: 10.1038/s41398-019-0457-y.

2.

Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51.

Tachon G, Cortes U, Guichet PO, Rivet P, Balbous A, Masliantsev K, Berger A, Boissonnade O, Wager M, Karayan-Tapon L.

Int J Mol Sci. 2018 Oct 3;19(10). pii: E3018. doi: 10.3390/ijms19103018.

3.

hRPE cells derived from induced pluripotent stem cells are more sensitive to oxidative stress than ARPE-19 cells.

Voisin A, Monville C, Plancheron A, Balbous A, Gaillard A, Leveziel N.

Exp Eye Res. 2018 Dec;177:76-86. doi: 10.1016/j.exer.2018.07.017. Epub 2018 Jul 24.

PMID:
30048622
4.

Motor Impairments Correlate with Social Deficits and Restricted Neuronal Loss in an Environmental Model of Autism.

Al Sagheer T, Haida O, Balbous A, Francheteau M, Matas E, Fernagut PO, Jaber M.

Int J Neuropsychopharmacol. 2018 Sep 1;21(9):871-882. doi: 10.1093/ijnp/pyy043.

5.

Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome.

Masliantsev K, Pinel B, Balbous A, Guichet PO, Tachon G, Milin S, Godet J, Duchesne M, Berger A, Petropoulos C, Wager M, Karayan-Tapon L.

Oncotarget. 2017 Dec 16;9(3):3968-3979. doi: 10.18632/oncotarget.23374. eCollection 2018 Jan 9.

6.

Crizotinib targets in glioblastoma stem cells.

Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L.

Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27.

7.

A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.

Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L.

BMC Cancer. 2016 Aug 5;16:604. doi: 10.1186/s12885-016-2647-9.

8.

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L.

Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22.

9.

A mesenchymal glioma stem cell profile is related to clinical outcome.

Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, Chomel JC, Karayan-Tapon L.

Oncogenesis. 2014 Mar 17;3:e91. doi: 10.1038/oncsis.2014.5.

Supplemental Content

Loading ...
Support Center